Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: Ready for prime time in predicting short-term outcome and recurrent disease?

American Journal of Neuroradiology

Volumn 30, Issue 4, 2009, Pages 681-688

  Bisdas, S ^a,b   Kirkpatrick, M ^a   Giglio, P ^a   Welsh, C ^a   Spampinato, M V ^a   Rumboldt, Z ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN BLOOD VOLUME; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE DURATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; KARNOFSKY PERFORMANCE STATUS; MALE; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; PERFUSION WEIGHTED IMAGING; PREDICTOR VARIABLE; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION;

ADULT; ASTROCYTOMA; BIOPSY; BLOOD VOLUME; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 64649086978     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A1465     Document Type: Article

References (25)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
2. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survivalthanhistologicalclassifica - tion. Cancer Res 2003;63:1602-07
3. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low - versus high-dose radiation therapy in adults with supratentorial low-grade glioma:initialreport ofa NorthCentralCancerTreatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20:2267-76
4. van den BentMJ,Kros JM. Predictive and prognostic markers in neuro-oncol - ogy. JNeuropathol Exp Neurol 2007;66:1074-81
5. Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in theinitialmanagement ofgliomas. Neuro Oncol 2001;3:193-200
6. Shin JH, Lee HK, Kwun BD, et al. Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. AJR Am JRoentgenol 2002;179:783-89
7. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventionalcontrast-enhancedMR:confoundingeffect ofelevatedrCBVof oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004;25:214-21
8. Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascularpermeabilityfromdynamicsusceptibilitycontrast-enhancedperfu - sionMR imagingwith glioma grade. AJNR Am J Neuroradiol 2004;25:746-55
9. Daumas-Duport C, Scheithauer B, O'Fallon J, et al. Grading of astrocytomas: a simpleand reproduciblemethod. Cancer 1988;62:2152-65
10. Law M, Oh S, Babb JS, et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging-prediction of patient clinical response. Radiology 2006;238:658 - 67
11. LawM, OhS, Johnson G, etal. Perfusionmagneticresonanceimagingpredicts patient outcome as an adjunct to histopathology: a second reference standard in thesurgical and nonsurgical treatment oflow-gradegliomas. Neurosurgery 2006;58:1099-107
12. Mineo JF, Bordron A, Baroncini M, et al. Low HER2- expressingglioblastomas aremoreoften secondaryto anaplastic transformation oflow-gradeglioma. J Neurooncol 2007;85:281-87. Epub 2007 Jun 15
13. Rosen BR, Belliveau JW, Vevea JM, et al. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249 - 65
14. Spampinato MV, Wooten C, Dorlon M, et al. Comparison of first-pass and second-bolus dynamic susceptibilityperfusion MRIin brain tumors. Neuro-radiology 2006;48:867-74
15. Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volumemeasure - ments in intracranial mass lesions: interobserver and intraobserver repro-ducibilitystudy. Radiology 2002;224:797-803
16. Piepmeier J, Christopher S, Spencer D, et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neuro-surgery 1996;38:872-78, discussion 878 - 79
17. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20:2076-84
18. Spampinato MV, Smith JK, Kwock L, et al. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 2007;188:204-12
19. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuro-pathol Exp Neurol 2005;64:479-89
20. Vinken PJ, BruynGW, VechtCJ. Neuro-Oncology.Amsterdam, the Netherlands: Elsevier; 1997
21. Chaskis C, Stadnik T,Michotte A, etal. Prognostic value of perfusion-weighted imaging in brain glioma: a prospective study. Acta Neurochir (Wien) 2006;148:277-85. Epub 2006 Jan 19
22. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopicim - aging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989 - 98
23. Maia AC Jr, Malheiros SM, da Rocha AJ, etal. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 2005;26:777-83
24. Showalter TN, Andrel J, Andrews DW, et al. Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys 2007;69:820-24
25. Carson KA, Grossman SA, Fisher JD, et al. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 2007;25:2601-06